AEMD

Aethlon Medical, Inc. 10-Q Summary

Business Context and Reporting Period

Company: Aethlon Medical, Inc. (AEMD)

Reporting Period: Quarterly period ended September 30, 2009 (Six months ended September 30, 2009).

Business Stage: Development stage medical device company. The Company focuses on the Hemopurifier(R) platform technology designed to remove viruses and toxins from blood. It has not generated significant revenue from principal operations and is seeking FDA approval for clinical trials.

Key Financial Metrics

Debt Profile: The Company holds significant debt obligations, including $310,501 in notes payable and $1,826,708 in convertible notes payable (net of discounts). As of September 30, 2009, $1,219,500 in principal of various promissory and convertible notes were past due and in default.

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by approximately $1.09 million (39%) compared to the prior six-month period, primarily due to a $621,178 reduction in interest expense. This reduction was driven by the amortization of note discounts, a significant portion of which were fully amortized by September 30, 2009.
• Operating Expenses: Increased by $83,514 (6%). This was driven by a $120,425 increase in professional fees (including investor relations and contract manufacturing setup) and a $17,548 increase in payroll expenses (due to higher stock-based compensation), partially offset by a $54,459 decrease in general and administrative expenses (lower lab supplies and insurance).
• Liquidity: Cash increased from $6,157 at March 31, 2009, to $92,429 at September 30, 2009. This increase was funded by net cash provided by financing activities of $1,027,620, offset by net cash used in operating activities of $931,635.
• Derivative Liability: A gain of $244,762 was recorded from the change in fair value of derivative liabilities, compared to a gain of $263,967 in the prior period.

Outlook, Risks, and Management Commentary

• Going Concern: The filing explicitly states that the Company's financial condition raises significant doubt about its ability to continue as a going concern. The Company has recurring losses, negative working capital, and is in default on certain debt.
• Capital Needs: Management estimates a minimum requirement of $150,000 per month to sustain operations. Additional capital is required to fund R&D, clinical trials, and debt obligations. The Company is actively seeking funds through debt and equity financing.
• Recent Financing: Subsequent to the reporting period (October-November 2009), the Company raised an additional $430,000 through the issuance of 10% convertible notes and warrants.
• Operational Milestones: The Company has filed an Investigational Device Exemption (IDE) with the FDA to proceed with human safety studies. It is also moving to new, lower-cost office and laboratory facilities.
• Risks: Key risks include the inability to raise additional capital, failure to obtain FDA approval, and the potential for litigation regarding unpaid debts or lease disputes (though a recent landlord dispute was settled).

Investor Verification Checklist

• Debt Default Status: Verify the current status of the $1.22 million in past-due notes and any potential acceleration clauses or legal actions by creditors.
• Cash Runway: Confirm the sufficiency of the $92,429 cash balance plus the $430,000 raised post-period against the stated $150,000 monthly burn rate.
• Dilution Risk: Assess the impact of outstanding convertible notes, warrants, and stock options (approx. 14.5 million options outstanding) on future share count, especially given the low conversion prices and "down-round" protections.
• Regulatory Progress: Monitor the status of the FDA IDE filing and the timeline for initiating human clinical trials.
• Related Party Transactions: Review the $619,331 "Due to related parties" liability and the terms of any new financing arrangements with insiders.